In previous clinical trials, supplementation of leptin, the signaling molecule produced by fat cells, produced moderate weight loss in some obese patients, purportedly by inhibiting hunger and promoting feelings of being full. Thus, this new work suggests possible new targets for treating obesity.
Reporting in the Oct. 29 online edition of the Proceedings of the National Academy of Science, Edythe London, a professor of psychiatry in the UCLA Semel Institute for Neuroscience and Human Behavior; Kate Baicy, a graduate student in London's lab, and colleagues report that leptin reduces activation in regions of the brain linked to hunger while enhancing activation in regions linked to inhibition and satiety. The findings suggest possible new therapeutic targets for human obesity, an increasing problem in adults as well as children.
The researcher's used functional magnetic resonance imaging (fMRI) to measure brain activity before and after leptin supplementation in three adults from a Turkish family who lacked the leptin (ob) hormone due to a mutation. Such a mutation in the ob gene causes leptin deficiency and morbid obesity.
The reason the study only involved three subjects, said London, is because having a genetic deficiency in leptin is extremely rare, so we were fortunate in finding them. Indeed, research published in 2005 by Julio Licinio, then at UCLA, used the same three family members to show that when leptin replacement was provided to them, body weight and eating behavior was normalized (Also in 2005, London and her team showed that leptin produced sustained changes in the tissue composition of the cerebral cortex in the same individuals.)
In order to determine the neural circuits through which leptin alters human feeding behavior, the researchers showed images of food to the adults both before and after leptin treatment, while fMRI imaging was taking place. After leptin replacement in these individuals, feelings of hunger induced by the images and activity in certain brain regions associated with hunger the insula, parietal, and temporal cortex were reduced, while brain activity increased in the prefrontal cortex, an area of the brain previously associated with feeling full or satisfied.
Despite the limitations in only having three subjects with the ob mutation, said London, we think knowing the mechanisms by which leptin alters brain function in congenital leptin deficiency can provide understanding of normal leptin physiology. Ultimately, that may help identify new targets for the treatment of obesity and related metabolic disorders.
ucla/
The Deal of Distinction Awards recognize transactions involving the licensing and transfer of intellectual property and creative and innovative solutions to business issues in contracts announced over the previous year. Awards are presented in five industry categories, including consumer products; chemicals, energy and materials; healthcare; and high technology.
"While a 2005 deal, the LES Deal of Distinction Award Committee supported this nomination given the element it felt was most distinctive, the promise by Mayo to broadly sublicense the intellectual property, was not completely fulfilled until 2006, when Mayo signed the first of several deals with several third parties," said the award citation. Revenue from Mayo Laboratories' testing and technology licensing supports medical education and research at Mayo Clinic.
Established in 1965, the Licensing Executives Society (U.S.A. and Canada) Inc. is composed of more than 6,000 members who are engaged in the transfer, use, development, manufacture and marketing of intellectual property. The LES membership includes business executives, lawyers, licensing consultants, engineers, academicians, scientists and government officials.
www-news.uchicago